2
项与 愈创甘油醚/对乙酰氨基酚/盐酸去氧肾上腺素 相关的临床试验A SingleDose Rand, TwoPeriod, Crossover Bioequivalence Study Between a Combination Tablet With Paracetamol, Guaifenesin and Penylephrine HCL (Wrafton Lab Ltd, UK) and Vicks Active SymptoMax Plus, Powder for Oral Solution (Wrafton Lab Ltd, UK) in Healthy Adult Volunteers
This is a single-dose, randomized, two-period cross-over study with 72 healthy male and female volunteers. The investigational products will be given (after fasting overnight) at separate visits separated by 7 ± 3 days. Blood for pharmacokinetic analyses will be drawn pre-dose and at 5, 10, 15, 20, 25, 30, 40, 60, 75, 90, 105 minutes, as well as 2, 2.25, 3, 4, 5, 6, 8, and 12 hours after drug administration. Subjects will also be monitored to capture any adverse events that may occur. Bioequivalence will be assessed based on the single-dose pharmacokinetics of paracetamol, guaifenesin and phenylephrine, respectively
Alpha-Adrenoceptor Vascular Function In Chronic Kidney Disease Focus On The Role Of Endothelial Nitric Oxide
The purpose of this study is to learn more about why most patients with early stages of kidney disease have high blood pressure.
We know the body produces natural substances that cause blood vessels to open wider to carry more blood when needed. An example is during exercise. Other natural substances cause blood vessels to get smaller and slow down blood flow when needed. An example is when people are cold. The balance between these substances is important. People with kidney disease and high blood pressure do not have the normal balance of these substances.
This study will include 3 groups of people, people with normal blood pressure, people with high blood pressure and people with kidney disease.
* Subjects will have a screening physical examination, including an ECG and laboratory tests
* Subjects with high blood pressure may not take their regular blood pressure medication for 3 weeks prior to the inpatient GCRC study
* Subjects will be given intra-arterial medications that will cause changes in the blood vessels during the in-patient study.
The study will then compare the responses of the three groups. A GFR test will be done to confirm the renal function of the group with chronic kidney disease.
These studies will provide insight into the mechanisms of the pathogenesis of enhanced α1 vasoreactivity in subjects with progressive renal disease. This will lay the groundwork for new strategies in the treatment and prevention of vascular disease among the rapidly growing group of individuals with CKD.
100 项与 愈创甘油醚/对乙酰氨基酚/盐酸去氧肾上腺素 相关的临床结果
100 项与 愈创甘油醚/对乙酰氨基酚/盐酸去氧肾上腺素 相关的转化医学
100 项与 愈创甘油醚/对乙酰氨基酚/盐酸去氧肾上腺素 相关的专利(医药)
100 项与 愈创甘油醚/对乙酰氨基酚/盐酸去氧肾上腺素 相关的药物交易